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Dear Subscriber,
On the following pages you will find four documents:
1) A Patient Handout on the several “dangerous” drugs that have been in the news since the
FDA official told Congress about them. This Patient Handout covers Celebrex, Crestor, and
several others.
2) A Patient Handout on JUST the COX-2 inhibitors and naproxen (Aleve, Naprosyn) for you to
use if patients are asking about only these.
3) An FDA Talk Paper on use of COX-2 inhibitors and non-selective NSAIDs.
4) Professional Information for you covering all of these drugs.
You may use your choice of either (or both) of the Patient Handouts to suit your needs. Active
subscribers have our permission to reproduce copies of the Patient Handouts for you to hand to
your own patients. (Mass reproduction or electronic forwarding or dissemination is not
authorized.)
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Patient Handout

“Seven Dangerous Drugs” in the News
There have been a lot of recent news reports about some prescription drugs that may be
dangerous. These new reports started when Congress was holding a hearing about the painkiller,
Vioxx, that was taken off the market.
During a Congressional hearing an FDA staff member raised concerns about the safety of
some other drugs. He named several drugs: Accutane (isotretinoin), Arava (leflunomide), Bextra
(valdecoxib), Crestor (rosuvastatin), Lotronex (alosetron), Meridia (sibutramine), and Serevent
(salmeterol).
Since the Congressional hearing there have been new reports about two drugs related to
Vioxx. The two painkiller drugs are Celebrex (celecoxib) and Bextra (valdecoxib). Recently,
Bextra was also withdrawn because of the reported problems.
It is important to remember that millions of patients have taken all of these drugs, and the
chance of any serious problem is very small. Here is information on the drugs that have been in
the news:

Accutane (isotretinoin)
Many people take Accutane for severe acne. It is a very effective medicine. It’s well-known
that Accutane can cause birth defects. The problem is that pregnancies continue to occur in
women taking Accutane despite strict registration programs and mandatory pregnancy blood
tests. Part of the problem is that some people get Accutane from a friend or from another
country.
Women shouldn’t take Accutane unless they can take strict precautions to avoid getting
pregnant. Women who are sexually active should always use two different forms of effective
birth control. They shouldn’t allow themselves to become pregnant for at least a month after
stopping Accutane.
Accutane can also make some patients feel depressed, irritable, or lead to suicidal thoughts.
There have been suicides in patients taking Accutane. Be certain to tell your physician and/or
pharmacist right away if you have feelings of depression or self-harm while taking Accutane.

Arava (leflunomide)
Arava is an effective drug for treating severe rheumatoid arthritis. Over the years there have
been reports of serious lung or liver problems, but these are rare. Patients on Arava should get
frequent liver function tests to detect any liver problems that might occur. Patients should also
report any symptoms of liver problems such as unusual nausea, abdominal pain, fatigue, dark
urine, pale stools, or yellow-looking eyes or skin. If a person has any sign of infection that lasts
more than a few days, the patient should see a doctor. The signs of infection to watch for are a
fever of or above 100.5 degrees, chills, severe sore throat, ear or nose pain, cough, or colored
sputum. These might indicate a lung problem.
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Patient Handout

“Seven Dangerous Drugs” in the News
Bextra (valdecoxib) and Celebrex (celecoxib)
Bextra and Celebrex (celecoxib) are used mainly for arthritis pain, menstrual pain, or other
pain. Many experts are concerned that Bextra and Celebrex can lead to an increased chance of
heart problems or stroke. Bextra and Celebrex are similar to Vioxx which was just taken off the
market due to these types of problems. As of April 2005, Bextra is no longer available because
of these problems as well as the severe rash it can cause. For more information on Bextra’s
withdrawal from the market go to:
http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Bextra.
The chance of a problem in any one patient is very low, but since the problem seems to be
related to cardiovascular disease, it makes sense to try to avoid Celebrex in patients who have
heart problems.
Patients who have heart trouble and are taking Celebrex should talk with their health
professional.
People who are not likely to benefit from Celebrex may be better off on a regular NSAID
(such as Motrin or Advil or a store’s brand product) or acetaminophen (such as Tylenol or a
store’s brand product). Patients should discuss this with their pharmacist, NP, PA, or physician.
For more information on Celebrex go to:
http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Celebrex
http://www.fda.gov/bbs/topics/news/2004/NEW01144.html
http://www.pfizer.com/are/investors_releases/2004pr/mn_2004_1217.cfm
Just recently, the FDA issued a patient advisory statement on naproxen (Aleve, Naprosyn)
which can be bought over-the-counter. Preliminary information from an Alzheimer’s disease
study showed some evidence of increased risk of cardiovascular events in patients taking
naproxen. The FDA advises that patients should not exceed the recommended dose of 220 mg
twice daily for longer than ten days unless a physician directs otherwise.

Crestor (rosuvastatin)
Crestor is one of the statins used to lower cholesterol. The consumer group called Public
Citizen says it should be taken off the market because of possible kidney and liver problems. These
problems are rare and the risk can be minimized by using lower doses and checking kidney and
liver function. Anyone taking Crestor or another statin should call their health care professional if
they start to get muscle pain or weakness, unusual nausea, abdominal pain, fatigue, dark urine, pain
when urinating, pale stools, or yellow-looking eyes or skin.

Lotronex (alosetron)
Lotronex is used for women with Irritable Bowel Syndrome (IBS) who have diarrhea
frequently, and have failed to get better on other treatments. Reports have been in the news about
serious complications. About 1 woman out of 1,000 who takes Lotronex may get complications
such as severe constipation. It can also cause ischemic colitis, which is caused by low blood
flow to parts of the gut. About 1 woman out of 350 women who takes Lotronex over a 6 month
period may get this. Lotronex should never be used in patients who often have constipation.
There are other medications for diarrhea or irritable bowel syndrome that don’t have these
effects.
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Patient Handout

“Seven Dangerous Drugs” in the News
Meridia (sibutramine)
Meridia is modestly effective for weight loss, but it can increase blood pressure and heart rate.
There are reports of stroke and heart attack in patients taking Meridia, but it’s not known if these
are caused by the drug. Some obese patients already have high blood pressure or heart disease.
Patients taking Meridia should check their blood pressure and heart rate at least weekly and
report any sustained increases to their physician.

Serevent (salmeterol)
Serevent is used to prevent airway constriction in patients with asthma. It’s called a longacting bronchodilator. It may lead to an increased risk of severe asthma worsening, especially
when the medicine is not used appropriately. Serevent shouldn’t be used for sudden breathing
difficulties. A short-acting bronchodilator such as albuterol should be used for sudden breathing
problems. Also, Serevent should always be used with a drug that controls inflammation, such as
an inhaled steroid to control asthma and reduce the risk of flare-ups.

Remember
Every medicine has side effects. Your pharmacist, NP, PA, and physician know the possible
side effects of drugs and can carefully weigh the benefit of medicines against their risks. Your
health care professional will review possible side effects with you and give you information
about how to reduce these risks. Be sure to ask any questions you have when a drug is
prescribed or dispensed and while you are taking it. Always follow the medication instructions
that your health care professional gives you. Never share medications since this is a very
dangerous practice. Be sure to get your medicines from a trusted pharmacist.
If you have any concerns, please feel free to discuss them with the health care professional
who gave you this handout.
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Information for Patients Taking Celebrex or Naproxen
Celebrex (celecoxib) and naproxen (Aleve, Naprosyn) are used mainly for pain such as arthritis
pain. Many patients also use them for menstrual pain. Many experts are now concerned that
Celebrex and naproxen can lead to an increased chance of heart problems or stroke. Celebrex is
similar to Vioxx and Bextra which were taken off the market due to these types of problems.
Naproxen is a regular painkiller like Motrin or Advil.
The chance of a problem in any one patient is very low. It is important to remember that many
millions of people have used these medicines and many are still using them. Researchers
continuously conduct studies to learn more about the drugs. Recently, researchers were studying
to see if Celebrex was useful to prevent colon cancer. During the course of the study researchers
noticed that there was an increase in heart problems in the people who were taking Celebrex.
These studies usually run for years and involve many patients. In this case it requires statistical
calculations to determine that there was an increase in heart problems in the patients taking
Celebrex. Just recently, the FDA issued a patient advisory statement on naproxen (Aleve,
Naprosyn) which can be bought over-the-counter. Preliminary information from an Alzheimer’s
disease study showed some evidence of increased risk of cardiovascular events in patients taking
naproxen. Any individual patient who has taken Celebrex or naproxen should not become overly
concerned.
Since the problem seems to be related to cardiovascular disease, it makes sense to try to avoid
Celebrex in patients who have heart problems. Patients who have heart trouble and are taking
Celebrex or naproxen should talk with their health care professional to see if some other therapy
might be better for them.
Bextra, Celebrex, and Vioxx are called COX-2 inhibitor drugs. These drugs are actually in the
same family of drugs that are called nonsteroidal anti-inflammatory drugs (NSAIDs). One of the
problems with some nonsteroidal anti-inflammatory drugs (NSAIDs) is that they can sometimes
lead to bleeding in the stomach. It was thought that the COX-2 drugs such as Bextra, Celebrex,
and Vioxx would not lead to as much bleeding in the stomach as the other nonsteroidal antiinflammatory drugs (NSAIDs). So patients who had ulcers or other chance of bleeding in the
stomach or intestinal track often got a drug like Bextra, Celebrex, or Vioxx instead of the regular
nonsteroidal anti-inflammatory drugs (NSAIDs). Pharmaceutical firms encouraged physicians to
use these COX-2 drugs for many people. Many people might be better off on an NSAID (such as
Motrin, Advil, or a store’s brand product), or acetaminophen (such as Tylenol or a store’s brand
product). The FDA advises that patients should not exceed the recommended dose or duration
printed on any over-the-counter medicine bottle unless a physician directs otherwise. Patients
should discuss this with their pharmacist, nurse practitioner, physician assistant, and/or physician.
There was a separate concern related to Bextra. It could cause severe rash, which in some cases
was life-threatening. This reaction was unpredictable, and could happen after short or long
periods of use. In April 2005, the FDA asked Pfizer, the manufacturer of Bextra, to voluntarily
withdraw Bextra from the market.
For more information go to:
http://www.fda.gov/bbs/topics/news/2004/NEW01144.html
http://www.pfizer.com/are/investors_releases/2004pr/mn_2004_1217.cfm
http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Bextra
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FDA Issues Public Health Advisory
Recommending Limited Use of Cox-2 Inhibitors
The following excerpts are reprinted from the
December 23, 2004 FDA Talk Paper on
recommendations for limited use of COX-2 Inhibitors
http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01
336.html

Agency Requires Evaluation of Prevention
Studies Involving Cox-2 Selective Agents
The Food and Drug Administration (FDA)
today issued a Public Health Advisory
summarizing
the
agency's
recent
recommendations concerning the use of nonsteroidal anti-inflammatory drug products
(NSAIDs), including those known as COX-2
selective agents. The public health advisory is an
interim measure, pending further review of data
that continue to be collected.
In addition, FDA today announced that it is
requiring evaluation of all prevention studies that
involve the COX-2 selective agents Celebrex
(celecoxib) and Bextra (valdecoxib) to ensure that
adequate precautions are implemented in the
studies and that local Institutional Review Boards
re-evaluate them in light of the new evidence that
these drugs may increase the risk of heart attack
and stroke. A prevention trial is one in which
healthy people are given medicine to prevent a
disease or condition (such as colon polyps or
Alzheimer's disease).
FDA is issuing an advisory because of recently
released data from controlled clinical trials
showing that the COX-2 selective agents (Vioxx,
Celebrex, and Bextra) may be associated with an
increased risk of serious cardiovascular events
(heart attack and stroke), especially when they are
used for long periods of time or in very high risk
settings (immediately after heart surgery).
Also, as FDA announced earlier this week,
preliminary results from a long-term clinical trial
(up to three years) suggest that long-term use of a

non-selective NSAID, naproxen (sold as Aleve,
Naprosyn, and other trade name and generic
products), may be associated with an increased
cardiovascular (CV) risk compared to placebo.
Although the results of these studies are
preliminary and conflict with other data from
studies of the same drugs, FDA is making the
following interim recommendations:
Physicians prescribing Celebrex (celecoxib) or
Bextra (valdecoxib) should consider this emerging
information when weighing the benefits against
risks for individual patients. Patients who are at a
high risk of gastrointestinal (GI) bleeding, have a
history of intolerance to non-selective NSAIDs, or
are not doing well on non-selective NSAIDs may
be appropriate candidates for COX-2 selective
agents.
Individual patient risk for cardiovascular
events and other risks commonly associated with
NSAIDs should be taken into account for each
prescribing situation.
Consumers are advised that all over-thecounter (OTC) pain medications, including
NSAIDs, should be used in strict accordance with
the label directions. If use of an (OTC) NSAID is
needed for longer than ten days, a physician
should be consulted.
Non-selective NSAIDs are widely used in both
over-the-counter (OTC) and prescription settings.
As prescription drugs, many are approved for
short-term use in the treatment of pain and
primary dysmenorrhea (menstrual discomfort),
and for longer-term use to treat the signs and
symptoms of osteoarthritis and rheumatoid
arthritis. FDA has previously posted extensive
NSAID
medication
information
at
http://www.fda.gov/cder/drug/analgesics/default.h
tm.
FDA is collecting and will be analyzing all
available information from the most recent studies
of Vioxx, Celebrex, Bextra, and naproxen, and
More. . .
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other data for COX-2 selective and nonselective
NSAID products to determine whether additional
regulatory action is needed.
An advisory
committee meeting is planned for February 2005,
which will provide for a full public discussion of
these issues.
FDA urges health care providers and patients
to report adverse event information to FDA via
the MedWatch program by phone (1-800-FDA1088), by fax (1-800-FDA-0178), or via the
Internet
at:
http://www.fda.gov/medwatch/index.html.

The Public Health Advisory is available online
at: www.fda.gov/cder/drug/advisory/nsaids.htm.

Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.

Continue to the next page for more professional information.
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Professional Information

“Dangerous Medications” - Preventing Serious Side Effects
Lead author: Joseph A. Woelfel, Ph.D., FASCP, R.Ph., Assistant Editor

Background
Five drugs were recently cited as posing
serious risks as identified by an FDA scientist.
On November 18, 2004, Dr. David Graham
testified before the US Senate Committee on
Finance. Dr. Graham is the Associate Director for
Safety, Office of Drug Safety for the Food and
Drug Administration. In his presentation made at
the hearing on FDA, Merck and Vioxx: Putting
Patient Safety First, he identified five FDAapproved “dangerous drugs.” These include: the
diet drug Meridia, the cholesterol drug Crestor,
the acne medication Accutane, the antiinflammatory drug Bextra, and the asthma
medicine Serevent. In his written testimony on
Vioxx, he included the arthritis drug Arava, and
the irritable bowel agent, Lotronex.1
In his testimony, he further stated “I would
argue that the FDA as currently configured is
incapable of protecting America against another
Vioxx. We are virtually defenseless.” In response
to his testimony, Finance Committee Chairman,
Senator Chuck Grassley said “that’s exactly the
opposite of what it should be. The health and
safety of the public must be the FDA’s first and
only concern.”1
The risks associated with these FDA-approved
products that Dr. Graham identified are well
known. The larger concern is that there may be
system problems in checks and balances for rapid
drug approval vs safety assurance.

Minimizing “Dangerous Drug” Effects
Appropriate
prescribing,
dispensing,
administration, and monitoring of medication use
are essential for assurance of patient safety.
Accutane (isotretinoin)-related birth defects
and suicide or mental problems are well known.
In 2002 an isotretinoin risk management program
known as the System to Manage Accutane Related
Teratogenicity (S.M.A.R.T.) was implemented.

Currently the FDA is taking action to strengthen
the risk minimization action plan (RiskMAP) for
Accutane
and
the
generic
equivalents.
Registration of prescribers, pharmacists, and
patients will be required before dispensing of
isotretinoin. Pregnancy testing before and during
isotretinoin is required.2
The FDA Accutane Medication Guide is
essential reading for all patients with each new or
refill prescription. Remind them to report any
feelings of depression or suicide and for women to
use two different forms of birth control.3
Arava (leflunomide) for rheumatoid arthritis
carries similar pregnancy warnings and
contraindications. Women wanting to become
pregnant after receiving Arava must undergo a
process using cholestyramine taken orally for
eleven days to clear residual leflunomide from
their system. Interstitial lung disease is a serious
but rare adverse reaction which was included in
the November 2004 product label as a result of
post-marketing surveillance data. It can occur any
time during treatment. New onset or worsening
pulmonary symptoms, such as cough and dyspnea,
with or without associated fever, may be a sign of
the often fatal problem and warrants follow-up or
discontinuation.
Arava can cause hepatic
problems. An unacceptable risk of liver failure
was mentioned by Dr. Graham. Monitoring liver
function should occur at baseline, at six and 12
weeks after the start of therapy or dose elevation,
then every six months.4 Patients should be
reminded to report any signs of liver toxicity such
as nausea, abdominal pain, dark urine, or
jaundice.
Bextra (valdecoxib) had a new black box
warning, added in November 2004. Serious skin
rashes can occur anytime but usually occur within
the first two weeks of therapy. Advise patients to
watch for rashes, lesions, or unusual swelling and
discontinue Bextra at the first sign of these. They
More. . .
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should immediately call their health care
professional when this occurs. Patients who are
recovering from coronary artery bypass graft
(CABG) surgery should not receive Bextra. In
this group of patients Bextra is contraindicated
due to cardiovascular thromboembolic adverse
events. A new bolded warning was added to the
label.6 In recent correspondence to the editor
published in the New England Journal of
Medicine, it was suggested that Bextra’s use be
limited
until
convincing
evidence
of
cardiovascular safety is shown.7 On April 7, 2005
the FDA requested that Pfizer withdraw Bextra
from the market.15 For more information on
Bextra’s
withdrawal
go
to:
http://www.fda.gov/medwatch/SAFETY/2005/saf
ety05.htm#Bextra.
Crestor (rosuvastatin) like other statins can
cause rhabdomyolysis or hepatotoxicity. Patients
should report any muscle pain or weakness as well
as any signs of liver problems such as yellow skin
or sclera. The consumer advocacy group, Public
Citizen, has admonished Crestor for causing
kidney damage and rhabdomyolysis. Kidney
disease can increase the incidence of
rhabdomyolysis and requires dosage adjustment.
For patients with severe renal impairment (CL cr
<30 mL/min/1.73m2) who are not on
hemodialysis, a starting dose of 5 mg once daily is
recommended and should not exceed 10 mg once
daily.
Doses above 10 mg should not be
administered to patients taking gemfibrozil
(Lopid). Initiation of therapy at a dose of 5 mg
once daily should be considered for all Asian
patients.
Lower starting doses are also
recommended for the elderly and patients with
untreated hypothyroidism.8
Lotronex (alosetron) for irritable bowel
syndrome lasting over six months in women was
withdrawn from the market and then re-introduced
in 2002 through a supplemental new drug
application process.
The new label with
prescribing restrictions, black box warning, and a
Lotronex Risk Management Program reflected the
serious adverse events with its use. The incidence
of serious complications of constipation in women
was approximately 1 per 1,000 patients as shown
in clinical trials. The incidence of ischemic colitis
was 3 per 1,000 women over a 6 month period.9
Remind
women
receiving
Lotronex
to
immediately report any constipation, abdominal
discomfort, or intestinal bleeding.

Meridia (sibutramine) for weight loss can
increase blood pressure and also heart rate. Obese
patients may already present with underlying heart
and vascular problems so caution in prescribing is
essential. Meridia is another product under
scrutiny from Public Citizen because of these
potentially dangerous side effects.10 Tell patients
to check their blood pressure and heart rate
regularly, at least weekly, and report any
abnormal increases. Emphasize healthy lifestyle
changes.
Serevent (salmeterol) received a black box
warning label in 2003 concerning the rare but
significant risk of asthma-related death shown in
the Salmeterol Multi-center Asthma Research
Trial (SMART). The risk was greater in African
Life-threatening
American asthma patients.11
asthma exacerbation can be reduced by use of an
inhaled corticosteroid as recommended in the
National Asthma Education and Prevention
Program (NAEPP) guidelines.12 Patients should
also receive a short-acting bronchodilator for “as
needed” bronchospasm use.
Celebrex (celecoxib). On December 17, 2004,
Pfizer issued a news release that in the Adenoma
Prevention with Celecoxib (APC) trial, patients
taking 400 mg and 800 mg of Celebrex daily, had
an approximately 2.5 fold increase in major fatal
or non-fatal cardiovascular events compared with
placebo. As a result of this finding the APC colon
cancer prevention trial was stopped. Though
higher-than-recommended doses were used in the
trial, these findings further raise safety concerns.13
For more information go to:
http://www.fda.gov/medwatch/SAFETY/2004/saf
ety04.htm#Celebrex
http://www.fda.gov/bbs/topics/news/2004/NEW0
1144.html
http://www.pfizer.com/are/investors_releases/200
4pr/mn_2004_1217.cfm
On December 20, 2004, the FDA issued a
patient advisory statement on naproxen (Aleve,
Naprosyn). Preliminary information from an
Alzheimer’s disease study showed some evidence
of increased risk of cardiovascular events in
patients taking naproxen. The FDA advises that
patients should not exceed the recommended dose
of 220 mg twice daily for longer than ten days
unless a physician directs otherwise.14
On April 7, 2005 the FDA announced that
manufacturers of all marketed prescription
NSAIDs, including Celebrex revise the labeling
More. . .
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for their products to include a boxed warning and
a Medication Guide.
The boxed warning
highlights the potential for increased risk of
cardiovascular events and the potentially lifethreatening gastrointestinal bleeding associated
with their use.
A Medication Guide must
accompany every prescription NSAID at the time
of dispensing to better inform patients about these
risks. The FDA asked manufacturers of nonprescription (OTC) NSAIDs to revise their
labeling to include more specific information
about the potential risks and provide information
to assist consumers in the safe use of the drug.15
Active involvement by patients in managing
their medication and health with health care
professionals’ reassuring guidance will minimize
the dangerous effects of these drugs.
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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